ID: ALA3623791

Max Phase: Preclinical

Molecular Formula: C69H105N21O17S2

Molecular Weight: 1564.86

Molecule Type: Protein

Representations

Canonical SMILES:  CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]3CCCN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N2

Standard InChI:  InChI=1S/C69H105N21O17S2/c1-5-35(3)54-64(103)79-40(18-11-23-75-69(73)74)57(96)83-45(32-91)59(98)80-41(17-9-10-22-70)66(105)90-26-14-21-50(90)68(107)89-25-13-20-49(89)63(102)87-55(36(4)6-2)65(104)85-46-33-108-109-34-47(61(100)86-54)84-58(97)42(27-37-30-76-39-16-8-7-15-38(37)39)78-53(94)31-77-56(95)43(28-51(71)92)81-62(101)48-19-12-24-88(48)67(106)44(29-52(72)93)82-60(46)99/h7-8,15-16,30,35-36,40-50,54-55,76,91H,5-6,9-14,17-29,31-34,70H2,1-4H3,(H2,71,92)(H2,72,93)(H,77,95)(H,78,94)(H,79,103)(H,80,98)(H,81,101)(H,82,99)(H,83,96)(H,84,97)(H,85,104)(H,86,100)(H,87,102)(H4,73,74,75)/t35-,36-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,54-,55-/m0/s1

Standard InChI Key:  AOMZQHHLSHFCGW-LQFZIJPOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Protein

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1564.86

Molecular Weight (Monoisotopic): 1563.7439

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. de Veer SJ, Wang CK, Harris JM, Craik DJ, Swedberg JE..  (2015)  Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.,  58  (20): [PMID:26393374] [10.1021/acs.jmedchem.5b01148]

Source

Source(1):

• Scientific Literature